Landec Corporation Stock News

Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.

-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance ; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at ...

Lifecore Biomedical is positioned for margin expansion and likely acquisition, supported by industry trends and potential M&A multiples above current share price. NextNav is favorably placed for FCC spectrum approval, with strong national security tailwinds and potential for significant share price appreciation upon monetization. SECURE Waste Infrastructure offers downside protection, recurring...

CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close.

CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with r...

June saw a record number of 48 new Seeking Alpha analysts, each bringing fresh stock ideas and unique backgrounds to the platform. Analysts provided ratings from Sell to Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on Alphabet, TSM, AppLovin, and Rolls-Royce, a bearish call Samsara, an...

Lifecore Biomedical is emerging from a challenging restructuring and is now a pure play CDMO with new management, an improved balance sheet, expanded capacity, and a solid business plan. Industry dynamics and recent M&A suggest a decent chance of a near-term acquisition, potentially valuing LFCR at 2x its current price. LFCR's growth runway and customer stickiness support its premium valuation,...

CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer.